HUTCHMED and GSK announce $1.3B deal for KRAS-EGFR antibody conjugate
HUTCHMED announced a licensing and co-development deal with GSK for a novel KRAS-EGFR antibody conjugate. The agreement includes $1.3 billion in potential value, with HUTCHMED leading phase I trials and GSK taking over ex-China development.
A major licensing and co-development deal was announced with GSK for a novel KRAS-EGFR antibody conjugate, validating the ATTC platform and accelerating global development.
The agreement includes $1.3 billion in potential value, with HUTCHMED leading phase I trials and GSK taking over ex-China deve…